Gorsky says no tax inversion for J&J; FDA seeks advice on risks of testosterone drugs; Lilly unhappy about India's price caps;

@FiercePharma: AbbVie finally gets Shire, and oh so much more. News | Follow @FiercePharma

@TracyStaton: $GSK just can't escape China questions. Ex-workers sue, news of 2001 corruption breaks. More | Follow @TracyStaton

@EricPFierce: Teva says it is cooperating with probe by Israel into source of blood infections taking Teva product. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Dengue, polio and a less-than-ideal Q2 for the $NVS vax unit. All in this week's issue of FierceVaccines. Issue | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) CEO Alex Gorsky says the company is not scouting for any deal that would allow it to do a tax inversion as many competitors have. Story

> The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17 to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy. Item

> More than 100 people killed on the Malaysian Airlines flight that is believed shot down over the Russian-Ukraine border were headed for the AIDS 2014 conference in Australia. Story

> The National Institute for Health and Care Excellence (NICE) is recommending treatments for anyone with a 10% risk of developing cardiovascular disease to be put on treatment that could include a statin, which compares with the current standard of 20% risk. Article

> Eli Lilly ($LLY) has expressed concerns about India's broadening of price controls on drugs. Story

Medical Device News

@FierceMedDev: Stryker delivers positive Q2 numbers but stays mum on inversion. Story | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. More | Follow @MichaelGFierce

@EmilyWFierce: AbbVie found its pot of gold at the end of the rainbow, scooping up Shire and saving an estimated $1.3B by 2020. Article | Follow @EmilyWFierce

> Investments in Minnesota life science companies take big Q2 jump. Story

> Baxter International gets Q2 infusion from acquisition of Swiss dialysis outfit. Article

> Venture capitalist spending bonanza lifts med tech investment in Q2. Report

Biotech News

@FierceBiotech: This week's hirings and retirings: Merck KGaA brings on U.S. Merck's Rossetti to head R&D. More | Follow @FierceBiotech

@DamianFierce: AbbVie's Gonzalez says inversion debate should shift toward tax reform, "making U.S. companies more competitive in the global economy." | Follow @DamianFierce

@EmilyMFierce: Extra dose of inactivated polio vaccine provides greater protection in children. Story | Follow @EmilyMFierce

> Biotech VCs bet $1.8B in a colossal Q2. Report

> Baxter International gets Q2 infusion from acquisition of Swiss dialysis outfit. Story

> Amgen's kidney dialysis drug clears its first Phase III hurdle. Article

And Finally... AstraZeneca ($AZN) says that its new R&D center in Cambridge, U.K., will include glass-walled labs to promote "visible science." Story

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.